Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
$38.27
+5.3%
$39.55
$26.20
$63.50
$1.76B1.43565,052 shs644,589 shs
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$16.64
+3.9%
$18.74
$13.52
$35.25
$1.68B2.222.52 million shs2.39 million shs
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
$8.19
+6.8%
$7.80
$6.85
$19.89
$483.82M-0.08381,468 shs629,410 shs
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
$12.58
+2.9%
$10.23
$6.36
$46.81
$1.79B1.083.04 million shs2.30 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
0.00%+2.63%-8.09%-3.06%-20.85%
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
0.00%-6.62%-20.57%-1.13%-34.72%
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
0.00%+6.92%-1.68%+4.87%-54.55%
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
0.00%+1.62%+36.15%+7.61%-73.26%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
3.7747 of 5 stars
4.43.00.00.02.64.20.0
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
2.2261 of 5 stars
3.50.00.00.02.72.50.6
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
1.9401 of 5 stars
3.50.00.00.02.71.70.6
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
3.6298 of 5 stars
4.51.00.00.02.85.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
2.86
Moderate Buy$99.00158.69% Upside
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
3.07
Buy$48.45191.19% Upside
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
3.00
Buy$26.80227.23% Upside
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
3.00
Buy$33.80168.68% Upside

Current Analyst Ratings Breakdown

Latest CGEM, BEAM, DYN, and APGE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/21/2025
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$24.00
8/18/2025
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$35.00 ➝ $28.00
8/14/2025
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
Zacks Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/11/2025
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$90.00
8/6/2025
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$25.00 ➝ $21.00
8/6/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$34.00 ➝ $13.00
7/31/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$66.00 ➝ $36.00
7/29/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$25.00 ➝ $23.00
7/29/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$37.00 ➝ $31.00
7/29/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$50.00 ➝ $38.00
7/21/2025
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
N/AN/AN/AN/A$15.92 per shareN/A
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$63.52M26.50N/AN/A$8.86 per share1.88
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
N/AN/AN/AN/A$10.14 per shareN/A
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
N/AN/AN/AN/A$6.19 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
-$182.15M-$4.13N/AN/AN/AN/A-34.65%-32.76%11/11/2025 (Estimated)
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-$376.74M-$4.50N/AN/AN/A-661.31%-43.15%-31.06%11/4/2025 (Estimated)
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
-$167.38M-$3.23N/AN/AN/AN/A-36.56%-34.82%11/6/2025 (Estimated)
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-$317.42M-$3.86N/AN/AN/AN/A-64.12%-56.75%11/11/2025 (Estimated)

Latest CGEM, BEAM, DYN, and APGE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2025Q2 2025
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
-$1.03-$1.13-$0.10-$1.13N/AN/A
8/7/2025Q2 2025
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
-$0.83-$1.07-$0.24-$1.07N/AN/A
8/5/2025Q2 2025
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-$1.04-$1.00+$0.04-$1.00$13.29 million$8.47 million
7/28/2025Q2 2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-$0.99-$0.97+$0.02-$0.97N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
N/AN/AN/AN/AN/A
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
N/AN/AN/AN/AN/A
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
N/AN/AN/AN/AN/A
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
N/A
16.36
16.36
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
N/A
6.75
6.75
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
N/A
9.83
9.83
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
0.17
16.83
16.83

Institutional Ownership

CompanyInstitutional Ownership
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
79.04%
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
99.68%
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
86.31%
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
96.68%

Insider Ownership

CompanyInsider Ownership
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
42.77%
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
3.50%
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
6.07%
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
20.77%
CompanyEmployeesShares OutstandingFree FloatOptionable
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
9146.11 million26.39 millionOptionable
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
510101.16 million97.62 millionOptionable
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
3059.07 million55.49 millionOptionable
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
100142.26 million112.72 millionOptionable

Recent News About These Companies

DYNE-251 for DMD granted FDA breakthrough therapy designation

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Apogee Therapeutics stock logo

Apogee Therapeutics NASDAQ:APGE

$38.27 +1.92 (+5.28%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$37.25 -1.02 (-2.67%)
As of 08/22/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Beam Therapeutics stock logo

Beam Therapeutics NASDAQ:BEAM

$16.64 +0.63 (+3.94%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$16.71 +0.07 (+0.42%)
As of 08/22/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Cullinan Therapeutics stock logo

Cullinan Therapeutics NASDAQ:CGEM

$8.19 +0.52 (+6.78%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$8.46 +0.28 (+3.36%)
As of 08/22/2025 06:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Dyne Therapeutics stock logo

Dyne Therapeutics NASDAQ:DYN

$12.58 +0.36 (+2.95%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$12.58 0.00 (0.00%)
As of 08/22/2025 05:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.